Clinical trials: Ovarian Cancers
HIV Infection, Recurrent Anal Cancer
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
This phase I clinical trial is studying the side effects and the best dose of vorinostat when given together with paclitaxel and carboplatin in treating patients with metastatic or recurrent solid tumors and human…
- Conditions
- HIV Infection, Recurrent Anal Cancer, Recurrent Breast Cancer, Recurrent Esophageal Cancer
- Trial name
- NCT01249443
- Testing
- vorinostat, diagnostic laboratory biomarker analysis, pharmacological study
- Where
- 10 sites in United States
- Volunteers
- 17 people
- Sponsor
- AIDS Malignancy Consortium
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
Drugs used in chemotherapy, such as 3-AP and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
- Trial name
- NCT00081276
- Testing
- triapine, cisplatin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Breast Cancer
A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)
This study will determine the best doses of docetaxel and lonafarnib when the two anti-cancer agents are used in combination. Patients with tumors for which treatment with docetaxel would be appropriate are eligible.
- Conditions
- Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer
- Trial name
- NCT00539968
- Testing
- Docetaxel plus lonafarnib
- Volunteers
- 5 people
- Sponsor
- Merck Sharp & Dohme LLC
High Grade Ovarian Cancer, Primary Peritoneal Cancer
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum sensitive, high-grade…
- Conditions
- High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT05456685
- Testing
- Mirvetuximab soravtansine, Carboplatin
- Where
- 69 sites in United States, Belgium and 4 more
- Volunteers
- 125 people
- Sponsor
- AbbVie
Ovarian Carcinoma, Endometrial Carcinoma
Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies
The primary trial objective is to determine the efficacy of KPT-330 (selinexor) in participants with advanced or metastatic gynaecological cancers by disease control rate (complete response (CR) or partial response (PR) or stable…
- Conditions
- Ovarian Carcinoma, Endometrial Carcinoma, Cervical Carcinoma
- Trial name
- SIGN (NCT02025985)
- Testing
- Selinexor
- Where
- 4 sites in Belgium, Denmark
- Volunteers
- 116 people
- Sponsor
- Karyopharm Therapeutics Inc
Polycystic Ovary Syndrome, Ovulation Disorder
Clusterin Level and Polycystic Ovary Syndrome
Clusterin, a protein involved in metabolic syndrome, insulin resistance, and metabolic disorders associated with inflammation and oxidative stress such as atherosclerosis, Alzheimer's and some malignancies, has elevated levels in…
- Trial name
- NCT06601725
- Testing
- Clusterin level
- Where
- Turkey (Türkiye)
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Sanliurfa Mehmet Akif Inan Education and Research Hospital
Non Small Cell Lung Cancer, Advanced Solid Tumor
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in…
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma
- Trial name
- PRESERVE-001 (NCT04140526)
- Testing
- ONC-392, Pembrolizumab, Docetaxel
- Where
- 37 sites in United States, Australia
- Volunteers
- 733 people
- Sponsor
- OncoC4, Inc.
Breast Cancer Female, Ovarian Cancer
Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients
Safety and tolerability of combination of Nivolumab and Ipilimumab will be studied in patients with 3 different types of cancers in 3 parts of the study, as shown below: Part 1 - Neoadjuvant Therapy of Breast Cancer; Part 2 …
- Conditions
- Breast Cancer Female, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT03342417
- Testing
- Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- ExcellaBio LLC
Ovarian Cancer
Studying DNA in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer
RATIONALE: Studying tissue and blood samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00900289
- Testing
- DNA methylation analysis, microarray analysis, polymerase chain reaction
- Where
- 26 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Liz-Anne Lewsley
Visceral Adiposity Index, Polycystic Ovary Syndrome
Visceral Adiposity Index Differences Between Subtypes of Polycystic Ovary Syndrome
We aimed to investigate visceral adiposity index (VAI) in patients with different phenotype of policystic ovary syndrome (PCOS) and to compare healthy controls.
- Trial name
- NCT06358300
- Where
- Turkey (Türkiye)
- Volunteers
- 300 people
- Sponsor
- Uşak University
Ovarian Cancer
Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
The study was to evaluate the efficacy and safety of avelumab in combination with M6620 + carboplatin in participants with PARPi-resistant, recurrent, platinum sensitive ovarian, primary peritoneal, or fallopian tube cancer.
- Trial name
- NCT03704467
- Testing
- M6620, Avelumab, Carboplatin
- Where
- 13 sites in United States, Belgium and 1 more
- Volunteers
- 3 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Ovarian Epithelial Cancer, Fallopian Tube Cancer
A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
This is a Phase 1, open-label, dose-escalation ,and multidose study, aiming to investigate the safety, tolerability and pharmacokinetics of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary…
- Conditions
- Ovarian Epithelial Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT04029909
- Testing
- Gimatecan 0.6mg/m2/d, 0.8mg/m2/d, 0.4mg/m2/d
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Lee's Pharmaceutical Limited
Ovarian Cancer
Clinician Nudge to Referral of Adnexal Masses to Gynecologic Oncology
The goal of this study is to test the effectiveness of clinician nudges on referrals to gynecologic oncology in patients with suspected ovarian cancer.
- Trial name
- NCT07078409
- Testing
- Nudge
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Ovarian Cancer, Fallopian Tube Cancer
Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer
The overall aim of the study is to demonstrate a clinically meaningful extension of progression free survival using maintenance pembrolizumab.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- PROMPT (NCT03430700)
- Testing
- Pembrolizumab
- Where
- 4 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- University College, London
Cancer, Carcinoma
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
This study is a 2 part, 2 cohort, open-label, dose escalation/de escalation study of AMG 386 in combination with either pegylated liposomal doxorubicin or topotecan in subjects with recurrent ovarian cancer.
- Conditions
- Cancer, Carcinoma, Fallopian Tube Cancer, Gynecological Malignancies
- Trial name
- NCT00770536
- Testing
- A1: AMG 386 10 mg/kg + Liposomal doxorubicin, A3: AMG 386 15mg/kg + Liposomal doxorubicin, B1: AMG 386 10 mg/kg + Topotecan
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 103 people
- Sponsor
- Amgen
Endometrial Cancer
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
- Trial name
- NCT06463028
- Testing
- Sapanisertib, Serabelisib, Paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 40 people
- Sponsor
- Faeth Therapeutics
Hereditary Breast and Ovarian Cancer, Lynch Syndrome
Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch Syndrome
The purpose of this research study is to learn how cancer care providers can help their patients communicate the need for genetic testing in families with inherited cancer syndromes.
- Trial name
- NCT04508764
- Testing
- Families Accelerating Cascade Testing Toolkit
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Washington University School of Medicine
Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III
Molecular Ovarian Cancer Assessment in LatiNoAmerican PAtients
This is a multicentric observational study conducted at selected sites across Latin America. Eligible participants will be identified through the medical records of participating institutions.
- Conditions
- Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Fallopian Tube Cancer Stage III
- Trial name
- MOANA (NCT07771400)
- Where
- 17 sites in Argentina, Brazil and 2 more
- Volunteers
- 320 people
- Sponsor
- Latin American Cooperative Oncology Group
Malignant Ascites, Ovarian Cancer
Malignant Ascites in Ovarian Cancer: Impact of Total Paracentesis on Hemodynamics
The ATLANTIS-study was designed to determine the safety of a full paracentesis in patients with malignant ascites due to ovarian cancer.
- Conditions
- Malignant Ascites, Ovarian Cancer, Hemodynamic Instability
- Trial name
- ATLANTIS (NCT04032600)
- Testing
- Paracentesis
- Where
- Germany
- Volunteers
- 61 people
- Sponsor
- Charite University, Berlin, Germany
Ovarian Epithelial Cancer
Optimisation of Disease Management in Patients With Epithelial Ovarian Cancer in France
No structured organization for ovarian first line management emerges in France. Management across France seems to depend on regional contexts.
- Trial name
- Ovaire01 (NCT02981901)
- Testing
- Patient with ovarian epithelial cancer
- Where
- 3 sites in France
- Volunteers
- 376 people
- Sponsor
- Centre Leon Berard
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.